Report Highlights
Among high-tech industries, one of the most remarkable fields is the biopharmaceutical industry, which combines biology and the traditional pharmaceutical industry. Modern biology largely consists of genetic engineering, cell engineering, enzyme engineering, protein engineering and fermentation engineering, including epigenomics and bio-informatics. It provides strong tools for addressing a host of major issues faced by human beings. In particular, it plays a unique role in addressing diseases that are difficult to treat, population explosion and foot shortage. Therefore, governments in various countries around the world formulate preferential policies, implement development strategies, and invest heavily to develop biology.
In 2007, the most remarkable feature of China's biopharmaceutical industry was active capital operation. After the downturn in 2006, the periodic valley of China's pharmaceutical industry was recognized by capital, which proves the industry's huge potential. At the same time, we must see that China's biopharmaceutical industry is still on a low level compared with the international biopharmaceutical industry. China's biopharmaceutical industry still lags considerable behind advanced international level in enterprise size, strength and innovation capability and total investment in the industry.
On a global scale, the chemical pharmaceutical, traditional pharmaceutical, biopharmaceutical, biopharmaceutical engineering and medical instruments industries fall within the biopharmaceutical industry. In recent years, merger and reorganization have become new trend of the international pharmaceutical industry.
In the face of changes and challenges of competition and market, our team releases 2007-2008 Annual Report on the Development of China's Biopharmaceutical Industry, to help the government, investors and industry insiders grasp more accurately laws governing the industry's development and comb the development track of application value. The report describes and analyzes the present situation and development trend of the international and Chinese biopharmaceutical industries, assesses major enterprises in China's biopharmaceutical industry, and presents recommendations for investing in the industry.
?
Full and accurate research data and in-depth industry analysis: The report studies the global biopharmaceutical industry and depicts its development direction.
?
All-round and in-depth industry structure analysis: It presents the industry's blueprint, and grasps its development trend.
?
Scientific and complete industry forecast: Through regression modeling and expert verification in major industry segments, the report examines related links in the industry, and presents valuable trend analysis and quantitative forecast result.
Report Framework
Table of Contents
Definitions
Main Conclusions
Key Findings
Chapter I Overview of the Global Biopharmaceutical Industry in 2007
(I) Present Situation
1. Industry Size & Growth
2. Industry Structure
3. Industry Competition
4. Industry Transfer
(II) Basic Characteristics
1. Biopharmaceutical is industrialized in a massive way
2. The long payback period generates uncertainties
3. R&D outsourcing trend becomes more notable
4. Investment increases, M&As take place frequently
5. Strategic technology alliance is a successful model for developing new pharmaceutical products
6. Global pharmaceutical giants merge small pharmaceutical enterprises
(III) Major Countries & Regions
1. USA
2. Japan
3. Denmark
4. Singapore
5. UK
Chapter II Overview of China's Biopharmaceutical Industry in 2007
(I) Present Situation
1. Industry Environment: Regular policy spells bright prospects
2. Industry Size & Growth: Steady growth results in recovery of revenue
3. Industry Structure: The industry is stable
4. Profitability: Profit margin hits new highs
5. Investment in the Industry: High ROI, high risks
6. Independent Innovation Capability: Manifestation of core competitiveness
7. External Dependency: The industry has low external dependency
(II) Basic Characteristics
1. Despite the recovery of the pharmaceutical industry, industry environment becomes increasingly austere
2. Biopharmaceutical outsourcing experiences fast growth
3. China sells chemical raw materials in the international market
(III) Overview of Major Provinces & Municipalities
1. Hunan: developing industry clusters
2. Beijing: technological advantages fuel all-round development
3. Guangdong: there is lack of strong support for rapid development
4. Yunnan: holding unique advantages in pharmaceutical raw material resources
5. Liaoning: heavy investment ensures stable development
6. Hubei: utilizing advantages to pursue pharmaceutical park strategy
Chapter III Forecast of China's Biopharmaceutical Industry, 2008-2012
(I) Affecting Factors
1. Favorable Factors
2. Unfavorable Factors
(II) Size Forecast
(III) Industry Structure, 2008-2012
Chapter IV Development Trend of China's Biopharmaceutical Industry, 2008-2012
(I) Trend of Production & Consumption
(II) Trend of Product
(III) Trend of Technology Innovation
Chapter V Structure of the Industry Chain of China's Biopharmaceutical Industry
(I) Structure of the Industry Chain
1. Overview of the Industry Chain
2. Characteristics
(II) Evolution Trend of the Industry Chain
1. Lifecycle of Industry Chain
2. Flow of Value
3. Evolution Path & Trend
Chapter VI Competition Situation in the Industry Chain of China's Biopharmaceutical Industry in 2007
(I) Overall Competition Situation
1. Overall Competition Situation
2. Potential Entrants & Substitute Products
3. Distribution of Major Brands
(II) Leading Vendors' Competitive Strategies
1. Hualan Biological: tapping potential markets with main products
2. Kehua Bio-engineering: cementing its position in the industry with core technologies
3. Tiantan Biological: developing new products to seize market opportunities
4. SL Pharmaceutical: creating development space through channel marketing
Chapter VII Recommendations
(I) To the Government
(II) To Upstream Enterprises
(III) To Brand Enterprises
Tables
Development Trend of Emerging Diagnostic Reagents Worldwide
Sales Revenue & Growth Rate of Sub-Industries of China's Bio-Pharmaceutical Industry in 2007
Hualan Biological's Competitive Strategy
Kehua Bio-engineering's Competitive Strategy
Tiantan Biological's Competitive Strategy
SL Pharmaceutical's Competitive Strategy
Figures
Size & Growth Rate of the Global Pharmaceutical Market, 2000-2007
Size & Growth Rate of the Global Biopharmaceutical Market, 2000-2007
Share of the Biopharmaceutical Market in 2007
Development Trend of Genetic Engineering Biopharmaceuticals in the World in 2007
Development Trend of Antibody Drugs in the World in 2007
Development Trend of Vaccines in the World in 2007
Output Value of China's Pharmaceutical Industry in the First Half of 2007
Sales Revenue of China's Pharmaceutical Industry in the First Half of 2007
Structure of China's Biopharmaceutical Industry in 2007
Profit of China's Pharmaceutical Industry in the First Half of 2007
Forecast of the Size of China's Biopharmaceutical Industry, 2008-2012
Forecast of the Structure of China's Biopharmaceutical Industry, 2008-2012
Product Lifecycle
Distribution of Major Brands in China's Biopharmaceutical Industry in 2007
